Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy.
about
The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting gliaNeurological diseases and painSpinal interleukin-10 therapy to treat peripheral neuropathic painReciprocal modulation between microglia and astrocyte in reactive gliosis following the CNS injuryEnduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain.Regulatory T cells in multiple sclerosis and myasthenia gravis.Pathological pain and the neuroimmune interface.Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders.The regulatory effect of liuwei dihuang pills on cytokines in mice with experimental autoimmune encephalomyelitis.The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosisGlucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitroInterleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosisPioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes.Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administrationNeuropathic pain in animal models of nervous system autoimmune diseases.Effects of vaccination with altered Peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosisImmunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain.Long-term control of neuropathic pain in a non-viral gene therapy paradigm.IL-10 promotes neuronal survival following spinal cord injury.The therapeutic potential of interleukin-10 in neuroimmune diseases.Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE modelsCentral nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice.Immune modulation by curcumin: The role of interleukin-10.Behavioral assessment of neuropathic pain, fatigue, and anxiety in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy.Adenosine 2A receptor agonism: A single intrathecal administration attenuates motor paralysis in experimental autoimmune encephalopathy in rats.Anti-inflammatory effect by lentiviral-mediated overexpression of IL-10 or IL-1 receptor antagonist in rat glial cells and macrophages.Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues.IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4+ T Cell Migration.Learning new tricks from an old dog: using experimental autoimmune encephalomyelitis to study comorbid symptoms in multiple sclerosis.IL-1β Is Involved with the Generation of Pain in Experimental Autoimmune Encephalomyelitis.Gene Therapy for Autoimmune Disease.
P2860
Q24650739-984E063A-A935-4117-9E8B-DCEFCA41BF28Q26822891-0757ABD4-2EB4-4D28-A5C2-5EA37C4FA124Q26861391-B1CE9487-B014-4991-AC83-DF7056CBD677Q28389274-1EE08F3A-E15B-47E1-A131-791C24B3F550Q33562058-083218F0-7AA2-47D2-88C0-6B257BA5050FQ33784969-84314331-7309-4CEB-B300-63BFFABC2854Q33925677-6C9D0AE6-72B7-4922-8E61-4E3219AD01D4Q34054207-72642019-CB83-4BA5-B931-8D934F205F36Q34196541-501E8D49-2859-4166-939F-D908CF3C4CFDQ34413247-F8EDF38A-8E5B-4945-BFD9-2A36E7BE10D5Q35067385-6FFD6A29-6491-45D3-9F59-183D7048EFCFQ35078252-791E2284-48A1-481D-98FE-30EECD52065EQ36410286-87DC418C-A38D-4736-9938-266B4FA7DF00Q36642679-2CD0F8F6-924F-451A-85B3-127577F78A28Q36869524-FB54A90E-579C-41EC-B998-EAAF267850F1Q37261686-9B45B4B4-C41C-4F29-B75C-7CB82AE53166Q37388717-E4A064E6-228F-4290-A91A-3D0366298067Q37406988-CC9BF962-22CF-4131-9592-2019AB7C4950Q37460081-7FBAC04D-24F0-48E0-9BB5-03DA588D3E62Q37485007-CDD440AC-3F9A-4963-BF8B-A53DDB307CEBQ37601317-6DA673AA-E97A-4DAF-B08C-908980723C46Q37702246-F05E99B1-8016-4AF7-A636-52E870A78C65Q38729214-41DE59BC-A2D6-41F4-82D8-26B819807BCAQ39893541-7AA0E509-44ED-4C5F-B8ED-B32C5C3DBB8DQ40097338-2458432B-280E-474C-8496-85F04CD7ED04Q40749948-AC39B53E-B7E2-4731-94CD-B5EBAAD67D96Q41278261-317AF170-263B-4ECB-BDF2-FACF2FB81215Q45857204-60D41730-4E5D-4793-8CEF-02F61F0F64A1Q45874115-EA59AA60-894A-4707-A041-9F1DC7E4D6E3Q48172896-A2E645B6-1429-4213-9641-E9E2D664D4FEQ51849231-141559BA-F53F-4428-8E43-B009AEF5A309Q52978008-315E4191-A481-4390-8018-CFED3C0B16B1Q53014578-9F1C4AB4-3B9E-4886-83FD-0D34D09576C5
P2860
Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Anti-inflammatory cytokine gen ...... nt with cytokine gene therapy.
@en
type
label
Anti-inflammatory cytokine gen ...... nt with cytokine gene therapy.
@en
prefLabel
Anti-inflammatory cytokine gen ...... nt with cytokine gene therapy.
@en
P2093
P2860
P1476
Anti-inflammatory cytokine gen ...... ent with cytokine gene therapy
@en
P2093
A Ledeboer
A M Van Dam
E D Milligan
Evan Sloane
K W Johnson
L R Watkins
M van Strien
P2860
P304
P356
10.1016/J.BBI.2008.09.004
P577
2008-09-20T00:00:00Z